Acarbose vs Fisetin

Mechanism

Acarbose is a complex oligosaccharide that competitively inhibits alpha-glucosidase enzymes (maltase, isomaltase, sucrase, glucoamylase) in the brush border of the small intestinal enterocytes, delaying the digestion and absorption of dietary carbohydrates. This blunts postprandial glucose and insulin spikes, reducing glycemic variability. In the longevity context, chronic postprandial glucose/insulin reduction mimics aspects of caloric restriction signaling, potentially reducing mTOR activation, AGE formation, and oxidative stress. Undigested carbohydrates reaching the colon serve as prebiotics, increasing short-chain fatty acid (SCFA) production by gut bacteria.

Standard Dosing

Research indicates 25-100 mg taken with the first bite of each carbohydrate-containing meal, up to 3 times daily.

Timing

Must be taken with the first bite of a carbohydrate-containing meal — timing is critical for mechanism of action. Ineffective if taken without carbohydrates or after the meal.

Cycle Duration

Ongoing for longevity applications. Long-term use is well-established in diabetes management.

Side Effects

• Flatulence and bloating (very common — from colonic fermentation of undigested carbohydrates)
• Diarrhea
• Abdominal pain and cramping
• Elevated liver transaminases (rare, reversible — typically at doses >100 mg TID)

Contraindications

• Inflammatory bowel disease (Crohn's, ulcerative colitis)
• Intestinal obstruction or predisposition to obstruction
• Chronic intestinal diseases with maldigestion/malabsorption
• Severe renal impairment (creatinine >2.0 mg/dL)
• Cirrhosis
• Known hypersensitivity to acarbose
• GI intolerance
• IBD or bowel obstruction

Best Stacking Partners

Mechanism

Fisetin is a naturally occurring flavonol (3,7,3',4'-tetrahydroxyflavone) found in strawberries, apples, and persimmons that acts as a senolytic by inhibiting the PI3K/Akt/mTOR survival pathway and BCL-2 family anti-apoptotic proteins in senescent cells. It also activates sirtuin-mediated pathways (SIRT1), reduces NF-kB-driven inflammation, and scavenges free radicals as a direct antioxidant. Fisetin demonstrated the most potent senolytic activity among 10 flavonoids screened in a 2018 study, reducing senescent cell burden in aged mice and extending both healthspan and lifespan markers.

Standard Dosing

Research indicates 20 mg/kg/day for 2 consecutive days as an intermittent senolytic protocol (approximately 1400-2000 mg for a 70-100 kg individual).

Timing

Take with fat-containing meal for improved bioavailability (fisetin is lipophilic with poor water solubility). Liposomal or lipophilic formulations preferred.

Cycle Duration

Intermittent senolytic courses ongoing. Daily low-dose use for antioxidant/anti-inflammatory effects can be continuous.

Side Effects

• GI discomfort at high senolytic doses
• Diarrhea
• Headache
• Generally well-tolerated — no serious adverse events reported in clinical trials to date

Contraindications

• Known hypersensitivity to fisetin or flavonoids
• Pregnancy and breastfeeding (insufficient safety data)
• Active chemotherapy without oncologist coordination

Best Stacking Partners